Apoptosis among CD4+, CD8+, and CD56+ cells following allogeneic HCT
| . | CD3+ . | Apoptosis of PBMCs, % . | ||
|---|---|---|---|---|
| CD4+ . | CD8+ . | CD3−/CD56+ . | ||
| Median days after transplantation and total patients, | ||||
| 19-23 days, n = 51 | 30.4 ± 12.53-150 | 33.3 ± 14.63-150,3-151 | 26.0 ± 13.13-150 | 2.2 ± 1.2 |
| (5.1-60.0) | (4.3-68.6) | (5.9 ± 59.7) | (1.1-4.3) | |
| 10-14 months, n = 9 | 9.7 ± 2.83-150 | 11.8 ± 4.23-150 | 8.8 ± 2.53-150 | 2.6 ± 1.5 |
| (5.4-12.2) | (6.2-18.1) | (5.3-13.5) | (1.0-4.7) | |
| Controls, n = 17 | 4.0 ± 1.5 | 4.2 ± 1.6 | 3.8 ± 2.0 | 2.2 ± 1.5 |
| (1.9-6.9) | (1.8-6.9) | (1.4-8.3) | (0.6-4.2) | |
| . | CD3+ . | Apoptosis of PBMCs, % . | ||
|---|---|---|---|---|
| CD4+ . | CD8+ . | CD3−/CD56+ . | ||
| Median days after transplantation and total patients, | ||||
| 19-23 days, n = 51 | 30.4 ± 12.53-150 | 33.3 ± 14.63-150,3-151 | 26.0 ± 13.13-150 | 2.2 ± 1.2 |
| (5.1-60.0) | (4.3-68.6) | (5.9 ± 59.7) | (1.1-4.3) | |
| 10-14 months, n = 9 | 9.7 ± 2.83-150 | 11.8 ± 4.23-150 | 8.8 ± 2.53-150 | 2.6 ± 1.5 |
| (5.4-12.2) | (6.2-18.1) | (5.3-13.5) | (1.0-4.7) | |
| Controls, n = 17 | 4.0 ± 1.5 | 4.2 ± 1.6 | 3.8 ± 2.0 | 2.2 ± 1.5 |
| (1.9-6.9) | (1.8-6.9) | (1.4-8.3) | (0.6-4.2) | |
The percent of apoptosis plus or minus SD after a 24-hour culture of PBMCs. The range is indicated in parentheses. Patients were studied at 19-23 days or 10-14 months following transplantation. Four patients were studied at both 20-21 days and 12-14 months following transplantation. Of the 9 patients studied 10-14 months after transplantation, 7 were still receiving cyclosporine alone or cyclosporine and glucocorticosteroids. The median age (range) of the 17 controls was 34 years (18-50 years).
P < .05 compared with controls.
P < .05 compared with CD8+ T cells.